	US 12,084,676 B2
	Cas9 orthologs
Zhenglin Hou, Ankeny, IA (US); Joshua K. Young, Johnston, IA (US); Giedrius Gasiunas, Vilnius (LT); and Virginijus Siksnys, Vilnius (LT)
Assigned to PIONEER HI-BRED INTERNATIONAL, INC., Johnston, IA (US)
Filed by PIONEER HI-BRED INTERNATIONAL, INC., Johnston, IA (US)
Filed on Feb. 22, 2019, as Appl. No. 16/282,498.
Claims priority of provisional application 62/651,991, filed on Apr. 3, 2018.
Claims priority of provisional application 62/634,257, filed on Feb. 23, 2018.
Prior Publication US 2019/0264232 A1, Aug. 29, 2019
Int. Cl. C12N 15/90 (2006.01); C12N 9/22 (2006.01); C12N 9/78 (2006.01); C12N 15/10 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12N 15/52 (2006.01); C12N 15/85 (2006.01)

CPC C12N 15/907 (2013.01) [C12N 9/22 (2013.01); C12N 9/78 (2013.01); C12N 15/102 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/52 (2013.01); C12N 15/85 (2013.01); C12N 15/902 (2013.01); C07K 2319/00 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

43 Claims

1. A synthetic composition comprising a heterologous target polynucleotide and a Cas polypeptide comprising at least 90% amino acid sequence identity with SEQ ID NO: 120, wherein the Cas polypeptide recognizes a N(T>C>R)AGAN(A>K>C)NN PAM sequence, wherein N=A, C, G, or T; R=A or G; and K=G or T.